Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.

Christina M BrennanSandeep NadellaXiang ZhaoRichard J DimaNicole Jordan-MartinBreanna R DemestichasSam O KleemanMiriam FerrerEva Carlotta von GablenzNicholas MourikisMichael E RubinHarsha AdnaniHassal LeeTaehoon HaSoma PrumCheryl B SchleicherSharon S FoxMichael G RyanChristina PiliGary GoldbergJames M CrawfordSara GoodwinXiaoyue ZhangJonathan B PreallAna S H CostaJoseph ConigliaroJoseph R MasciJie YangDavid A TuvesonKevin J TraceyTobias Janowitz

Published in: Gut (2022)

Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomised trials are required.

Keyphrases

double blind
sars cov
clinical trial
placebo controlled
phase iii
phase ii
respiratory syndrome coronavirus
open label
study protocol
coronavirus disease
oxidative stress
electronic health record
sleep quality
single molecule
community acquired pneumonia